Prolific Machines Raises $50M to Scale Biomanufacturing Platform

SOSV SF portfolio company, Prolific Machines, which is transforming biomanufacturing with light-controlled, AI-optimized biotherapeutics, has raised an initial $50 million in a Series B2 financing led by Atoms & Bits and Nant Capital. The funding brings the company's total funding to more than $100 million.

Prolific Machines plans to use the capital to expand its platform across programs with pharmaceutical and biotechnology companies, increase staffing, and advance technology development and scale-up. Planned applications include biologics, biosimilars, and viral vectors, with early-stage work also planned for tissue and organ fabrication.